146 related articles for article (PubMed ID: 38263831)
21. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
22. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
[TBL] [Abstract][Full Text] [Related]
23. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
24. Dose response in prostate cancer with 8-12 years' follow-up.
Hanks GE; Hanlon AL; Epstein B; Horwitz EM
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
[TBL] [Abstract][Full Text] [Related]
25. Dosiomics improves prediction of locoregional recurrence for intensity modulated radiotherapy treated head and neck cancer cases.
Wu A; Li Y; Qi M; Lu X; Jia Q; Guo F; Dai Z; Liu Y; Chen C; Zhou L; Song T
Oral Oncol; 2020 May; 104():104625. PubMed ID: 32151995
[TBL] [Abstract][Full Text] [Related]
26. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
27. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
29. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
30. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
33. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer.
Ritter MA; Gilchrist KW; Voytovich M; Chappell RJ; Verhoven BM
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):574-80. PubMed ID: 12062599
[TBL] [Abstract][Full Text] [Related]
34. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
Gupta PK; Rastogi N; Maria Das KJ; Kumar S
J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer.
Sheinbein C; Teh BS; Mai WY; Grant W; Paulino A; Butler EB
Urology; 2010 Sep; 76(3):728-33. PubMed ID: 19616279
[TBL] [Abstract][Full Text] [Related]
36. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
Kestin LL; Goldstein NS; Vicini FA; Martinez AA
J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
[TBL] [Abstract][Full Text] [Related]
38. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
40. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
